| identifier: | ITN524ST |
| description: |
This study is for people who will receive a kidney transplant from a very well matched, living blood relative. After receiving a kidney transplant, a patient's immune system will think that the new kidney is a foreign invader and will try to attack or reject the transplanted kidney. Immunosuppressive drugs protect the transplanted kidney by suppressing the immune system. People who have kidney transplants must take immunosuppressive drug for the rest of their lives. If they stop, their immune system may reject the transplanted kidney. Immunosuppressive drugs make it hard for the body to fight off infections. In addition, they can cause high blood pressure, kidney damage, plaque build-up in the blood vessels, high cholesterol, diabetes and bone disease. They may also make the body more likely to get some types of cancer (mainly cancer of the white blood cells and/or skin) and other serious side effects.
Following surgery, kidney transplant patients must take medications in order to prevent rejection of their transplanted organ. These medications can be very effective. Called immunosuppressive drugs, they work by reducing the activity of the immune system. Because of this, however, they can also have serious side effects, including increased risks of serious infections and certain types of cancer.
The ITN Registry of Tolerant Kidney Transplant Recipients recently identified a rare group of people whose immune system has accepted their transplant without continued use of immunosuppressive drugs. Researchers have found that these patients have a unique pattern of cells and genes expressed in their blood compared to other transplant patients.
The ARTIST study will ask the questions "Are there other transplant patients who show this pattern?" and "If so, how often?"
The goal is to find out if there are other transplant patients who are taking immunosuppression who also show this pattern of genes. If there are others, then this pattern may one day be useful in identifying transplant patients who could reduce the dose of immunosuppression they need without fear of rejection.
Researchers are seeking adults who have received a kidney transplant within the past 1 to 5 years. Participants will be asked to attend 3 short appointments with study doctors over a period of 2 years. At these visits, doctors will request demographic and clinical information, relevant medical histories and blood and urine samples. Participants will be compensated for their time.
It is important to note that this is an observational study only. Other than receiving consultations and advice from the transplant team, there is no direct medical benefit to participating. However, by participating, patients may play an active part in helping doctors learn to control kidney transplant rejection more effectively, with fewer drugs.
|
| privacy: |
Not Provided
|
| aggregation: |
instance of dataset
|
| availability: |
available with registration
|
| relatedIdentifiers: |
ARTIST
|
| acknowledges: |
National Institute of Allergy and Infectious Diseases (NIAID)
|
| primaryPublications: |
28371372 20501946 |
| isAbout: |
Retention: Samples With DNA
Description:
Whole blood Isolation PBMC isolated RNA specimens
Renal Transplant Recipients
Subjects who received a kidney transplant within the past 1 to 5 years
Not Provided
|
| authorizations: |
registration required
|
| accessURL: |
https://clinicaltrials.gov/show/NCT01516177 |
| landingPage: |
https://www.itntrialshare.org/project/Studies/ITN524ST_landing/begin.view? |
| study type: | Observational |
| study phase: | |
| subject gender: | Sexes Eligible for Study: All |
| subject age: | 18 Years to 65 Years (Adult) |
| study category: | Transplant |
| study type: | Observational |
| name: |
Kidney Transplantation
|
| fullName: |
Anil Chandraker, MD
Kenneth Newell, MD, PhD
Laurence Turka, MD
|
| affiliations: |
Brigham and Women's Hospital
Emory University
Beth Israel Deaconess Medical Center
|
| roles: |
Study Chair
|
| name: |
Associating Renal Transplantation With the ITN Signature of Tolerance
|
| size: |
250
|
| output: |
The presence of at least one time point of the previously identified renal transplant tolerance signature. [ Time Frame: 2 years ]
Time course of potential changes in the previously identified renal transplant tolerance signature in individual participants. [ Time Frame: 2 years ]
Expression levels for a wide variety of genes measured by large-scale microarray or by PCR assessments [ Time Frame: 2 years ]
Flow-cytometric measurements of cell populations distinguished by cell-surface phenotype [ Time Frame: 2 years ]
Selected clinical events and laboratory parameters to assess hematologic and renal function [ Time Frame: 2 years ]
|
| identifier: |
NC
|
| selectionCriteria: |
Inclusion Criteria:
Received first kidney transplant from a living or deceased donor.
Kidney transplanted between 1 and 5 years ago.
Calculated GFR of greater than or equal to 45 mL/min/1.73 m2 within last 6 months
Ability to understand and provide informed consent.
Exclusion Criteria:
History of steroid-resistant acute rejection
History of two or more episodes of acute rejection
Any acute rejection in the past year
Current malignancy
Transplant of another organ
AIDS according to the CDC definition of AIDS.
|
| endDate: |
2014-04-01
|
| name: |
An Observational Study to Assess the Prevalence of a Tolerance Signature in Renal Transplant Recipients (ITN524ST/CTOT-12)
|
| description: |
This is an observational study for people who have received a kidney transplant within the past 1 to 5 years. Researchers in this study are looking for a certain pattern of genes and cells in the blood that has been found in a group of rare transplant patients who do not need immunosuppression. The study goal is to find out how common this pattern is in transplant patients, as a first step in determining if it can be used to personalize anti-rejection drug regimens better.
Following surgery, kidney transplant patients must take medications in order to prevent rejection of their transplanted organ. These medications can be very effective. Called immunosuppressive drugs, they work by reducing the activity of the immune system. Because of this, however, they can also have serious side effects, including increased risks of serious infections and certain types of cancer.
The ITN Registry of Tolerant Kidney Transplant Recipients recently identified a rare group of people whose immune system has accepted their transplant without continued use of immunosuppressive drugs. Researchers have found that these patients have a unique pattern of cells and genes expressed in their blood compared to other transplant patients.
The ARTIST study will ask the questions "Are there other transplant patients who show this pattern?" and "If so, how often?"
The goal is to find out if there are other transplant patients who are taking immunosuppression who also show this pattern of genes. If there are others, then this pattern may one day be useful in identifying transplant patients who could reduce the dose of immunosuppression they need without fear of rejection.
Researchers are seeking adults who have received a kidney transplant within the past 1 to 5 years. Participants will be asked to attend 3 short appointments with study doctors over a period of 2 years. At these visits, doctors will request demographic and clinical information, relevant medical histories and blood and urine samples. Participants will be compensated for their time.
It is important to note that this is an observational study only. Other than receiving consultations and advice from the transplant team, there is no direct medical benefit to participating. However, by participating, patients may play an active part in helping doctors learn to control kidney transplant rejection more effectively, with fewer drugs.
Observational Model: Cohort
Time Perspective: Prospective
|
| location: |
United States
|
| startDate: |
2010-09-01
|
| name: |
ITN TrialShare
|
| homePage: |
https://www.itntrialshare.org |